Aigen Investment Management LP Takes $572,000 Position in Integer Holdings Corporation (NYSE:ITGR)

Key Points

• Aigen Investment Management LP has acquired a new stake in Integer Holdings Corporation, purchasing 4,850 shares valued at approximately $572,000.
• Multiple hedge funds recently adjusted their positions in Integer, with notable investments including Raymond James Financial Inc. buying a $38 million stake in the company.
• Integer reported a quarterly EPS of $1.55, falling short of the consensus estimate of $1.57, yet its revenue was up 11.4% year-over-year, totaling $476 million.

Aigen Investment Management LP purchased a new stake in Integer Holdings Corporation (NYSE:ITGR - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,850 shares of the medical equipment provider's stock, valued at approximately $572,000.

A number of other large investors have also recently modified their holdings of ITGR. TD Private Client Wealth LLC grew its holdings in shares of Integer by 5.8% during the first quarter. TD Private Client Wealth LLC now owns 1,524 shares of the medical equipment provider's stock valued at $180,000 after buying an additional 83 shares during the last quarter. Xponance Inc. grew its position in Integer by 5.1% during the first quarter. Xponance Inc. now owns 2,518 shares of the medical equipment provider's stock valued at $297,000 after buying an additional 122 shares during the period. Bessemer Group Inc. raised its position in shares of Integer by 73.1% in the first quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 125 shares during the period. Emerald Mutual Fund Advisers Trust boosted its stake in shares of Integer by 0.8% during the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 19,867 shares of the medical equipment provider's stock worth $2,633,000 after acquiring an additional 152 shares in the last quarter. Finally, Summit Investment Advisors Inc. boosted its stake in shares of Integer by 5.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,488 shares of the medical equipment provider's stock worth $462,000 after acquiring an additional 175 shares in the last quarter. Hedge funds and other institutional investors own 99.29% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ITGR. Wells Fargo & Company lowered their target price on shares of Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a research note on Friday, July 25th. Benchmark decreased their price target on shares of Integer from $150.00 to $140.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Raymond James Financial decreased their price target on shares of Integer from $150.00 to $143.00 and set an "outperform" rating on the stock in a research note on Friday, July 25th. Truist Financial decreased their price target on shares of Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a research note on Friday, July 25th. Finally, Citigroup raised shares of Integer from a "hold" rating to a "strong-buy" rating and raised their target price for the stock from $133.00 to $140.00 in a research note on Thursday, May 22nd. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $140.25.

Insider Activity at Integer

In other Integer news, Director Donald J. Spence sold 14,739 shares of the business's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $120.38, for a total value of $1,774,280.82. Following the completion of the transaction, the director owned 18,781 shares in the company, valued at $2,260,856.78. The trade was a 43.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Martin C. Maxwell sold 8,720 shares of the business's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $120.56, for a total transaction of $1,051,283.20. Following the completion of the transaction, the director owned 22,170 shares of the company's stock, valued at approximately $2,672,815.20. This trade represents a 28.23% decrease in their position. The disclosure for this sale can be found here. 2.16% of the stock is currently owned by company insiders.

Integer Trading Down 2.6%

Shares of NYSE ITGR traded down $2.82 during midday trading on Thursday, reaching $106.76. 200,151 shares of the stock were exchanged, compared to its average volume of 487,422. The company has a 50 day simple moving average of $115.34 and a 200 day simple moving average of $120.63. The stock has a market capitalization of $3.74 billion, a P/E ratio of 47.03, a PEG ratio of 0.85 and a beta of 1.02. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41. Integer Holdings Corporation has a twelve month low of $104.93 and a twelve month high of $146.36.

Integer (NYSE:ITGR - Get Free Report) last posted its earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.02). Integer had a net margin of 4.61% and a return on equity of 12.27%. The company had revenue of $476.00 million during the quarter, compared to analyst estimates of $464.37 million. During the same quarter last year, the business posted $1.30 EPS. The firm's revenue for the quarter was up 11.4% on a year-over-year basis. As a group, equities analysts expect that Integer Holdings Corporation will post 6.01 earnings per share for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.